Estrogen is the single most important hormone for maintaining bone density in women. When it drops sharply at menopause, bone loss accelerates rapidly — up to 3–5% per year in the first years after menopause. HRT (hormone replacement therapy, also called menopausal hormone therapy or MHT) is one of the most effective tools for slowing that loss. Yet many Canadian women who could benefit aren't having the conversation.
Bone is not static tissue. It's constantly being broken down by osteoclasts and rebuilt by osteoblasts. Estrogen plays a critical regulatory role: it suppresses osteoclast activity (bone breakdown) and supports osteoblast function (bone building). Before menopause, this system stays roughly in balance. After menopause, estrogen withdrawal removes the brake on osteoclasts — and the breakdown-to-rebuilding ratio shifts sharply toward net loss.
In the first 5–7 years after menopause, women lose bone at an accelerated rate compared to the slower age-related loss that continues afterward. Women who enter surgical menopause (bilateral oophorectomy) before natural menopause have an even more abrupt estrogen withdrawal and correspondingly higher fracture risk if untreated.
The cumulative effect: the average Canadian woman loses 15–20% of her bone mass in the decade surrounding menopause. This is the window where intervention has the most impact.
The bone-protective effects of HRT are well-established and among the most consistent findings in women's health research:
Osteoporosis Canada recognizes menopausal hormone therapy as an effective option for fracture risk reduction in postmenopausal women. Their guidelines note:
The key practical implication: if you're in your late 40s or early 50s with menopausal symptoms and bone density concerns, HRT deserves a serious conversation with your GP or menopause specialist. It may be simultaneously the best treatment for your symptoms and your bones.
The 2002 WHI results caused a dramatic decline in HRT use among Canadian and American women. Understanding what the study actually showed — and what was over-interpreted — is important for making an informed decision now.
Key context that changed the interpretation:
| Type | Route | Examples in Canada | Key Considerations |
|---|---|---|---|
| Conjugated equine estrogen | Oral tablet | Premarin | Longest track record; first-pass liver metabolism |
| 17β-estradiol | Oral tablet | Estrace | Bioidentical; still first-pass metabolism |
| 17β-estradiol | Transdermal patch | Estradot, Climara, Vivelle | Lower clotting risk; bypasses liver; preferred for women with clot history risk |
| 17β-estradiol | Transdermal gel | Estrogel | Dose flexibility; no patch adhesive issues |
| 17β-estradiol | Transdermal spray | Evamist | Less common; same liver-bypass benefit as other transdermal forms |
Women who have not had a hysterectomy must take a progestogen alongside estrogen to protect the uterine lining from endometrial hyperplasia. Options in Canada:
| Province | Oral Estrogen | Transdermal Estrogen | Micronized Progesterone |
|---|---|---|---|
| Ontario (ODB) | ✅ Covered (Premarin, Estrace) | ✅ Covered (Estradot, Climara) | ✅ Covered (Prometrium) |
| British Columbia (PharmaCare) | ✅ Covered | ✅ Covered | ✅ Covered |
| Alberta (Drug Benefit) | ✅ Covered | ✅ Covered | ✅ Covered |
| Quebec (RAMQ) | ✅ Covered | ✅ Covered | ✅ Covered |
Most HRT formulations are covered under provincial drug plans with a standard prescription. Bioidentical compounded hormones from compounding pharmacies are not covered and their standardisation is less reliable than commercially manufactured products.
If you're a postmenopausal woman without menopausal symptoms, and your main concern is bone density, bisphosphonates remain the first-line recommendation from Osteoporosis Canada. They're specifically studied for fracture reduction in osteoporotic patients and have decades of safety data. See the osteoporosis medications guide for the full picture.
But HRT and bisphosphonates are not mutually exclusive, and some women use both. The more common scenario is using HRT primarily for symptom management while it also provides bone protection, then transitioning to a bisphosphonate if/when HRT is stopped, depending on bone density at that time.
| Approach | Bone Benefit (Approximate) | Duration of Effect After Stopping | Non-Bone Benefits |
|---|---|---|---|
| HRT (combined) | 34% hip fracture reduction; BMD gain 3–8% | Reverses within 1–2 years after stopping | Hot flashes, sleep, urogenital, mood |
| Bisphosphonates (alendronate) | ~50% vertebral fracture reduction; BMD gain 6–8% | Residual effect lasts years in bone | None specific beyond bone |
| Combination (HRT + bisphosphonate) | Additive BMD effect documented | Bisphosphonate effect persists | All above |
Unlike bisphosphonates, which are stored in bone and continue to exert effects after stopping, HRT's bone protection ends when the drug clears — typically within months. Bone turnover markers rise and BMD begins to decline after discontinuation.
For women stopping HRT, Osteoporosis Canada recommends:
The transition should be planned, not abrupt. Stopping HRT and waiting to see what happens to your bone density is not the recommended approach.
HRT is contraindicated or requires extra caution in women with:
In these cases, bisphosphonates, denosumab (Prolia), or other osteoporosis-specific agents are the appropriate alternative.
Your GP can refer you for a DEXA scan which is covered under most provincial plans when there's a clinical indication — and recent menopause with bone health concerns qualifies. If your GP isn't comfortable managing menopause-related bone health, a referral to an endocrinologist or menopause specialist is reasonable.
The Canadian Menopause Society (menopausecanada.ca) publishes position statements on HRT use that are broadly aligned with current international evidence. Their current position acknowledges that the benefit-risk profile for HRT is favourable for most healthy women under 60 who are within 10 years of menopause — and that bone protection is one of several legitimate reasons to consider it. They also acknowledge significant regional variation in prescribing comfort among Canadian GPs.
If your current healthcare provider is not current on the evidence, the Canadian Menopause Society's website has a provider finder to locate menopause-trained clinicians in your province.